NIH Plans Five Trial-Type Clinical Trial NOFOs to Replace Disease-Specific Funding Calls
November 20, 2026 · 6 min read
Granted Research Team · Editorial policy
For as long as most trialists have been writing NIH applications, the first question has been which institute owns the disease. A heart failure trial went to NHLBI, a migraine trial to NINDS, and a mental health trial to NIMH, each with its own funding opportunities, page limits and quirks.
NIH now plans to organize clinical trial funding by what kind of trial it is rather than which disease it studies. In a November 10 Extramural Nexus item titled "Simplifying the Landscape of NIH Clinical Trial Funding Opportunities," the agency described a suite of five cross-institute clinical trial Notices of Funding Opportunity (NOFOs), with one set of instructions for each trial type. Drug Discovery and Development and CASRAI both reported on the plan on November 13.
As of this week, none of the five NOFOs has been posted. That gives investigators planning trials in 2027 a few months to rethink how they position their applications.
The Five Trial Types
According to CASRAI's summary of the NIH item, the suite maps trial types to activity codes:
| Trial type | Activity code | Scope (as described) |
|---|---|---|
| Feasibility trials | R34 | Pilot work preparing for a larger trial |
| Early to definitive trials | R61/R33 | Phase I/Stage I through Phase II/Stage II (efficacy) |
| Multi-site trials | UG3/UH3 | Phase II or III; Stage III or IV |
| Pragmatic and implementation trials | UG3/UH3 | Phase III or IV; Stage IV or V |
| Network trials | UG3/UH3 | Trials run through established networks |
Drug Discovery and Development gives an example: a feasibility trial would use the same NOFO whether it studies heart disease, a neurological condition or anything else. Institutes would no longer signal their priorities by issuing disease-specific trial NOFOs. Instead they would use institute profile pages, strategic plans and Highlighted Topics.
NIH's stated goals, per CASRAI, are easier NOFO identification, consistent instructions for similar trial types, stronger methodological rigor, simpler co-funding across institutes, and better tracking of NIH's trial portfolio.
This Is a Plan, Not a Policy
Read the announcement carefully before rewriting a budget. CASRAI describes the item as "a plan under development, not a final policy." The forecasts are informational only, and nothing in the item changes current requirements. The NIH item gives no opening or due dates and cites no NIH Guide notice number.
The only timing on record is older. An NHLBI official presented the suite at the Society for Clinical Trials meeting in May 2026, and the slides said NIH "might publish the new NOFOs in late 2026 or early 2027," according to Drug Discovery and Development. NIH says it will roll the NOFOs out in phases, so the five types will probably not appear together.
Until a NOFO is posted in the NIH Guide, applications should follow the instructions and clinical trial designation of whichever NOFO they are submitted under.
Parent Announcements Stay
For many applicants, the most important detail is that the new NOFOs are meant to "sit alongside" the parent announcements for clinical trial research project grants (R01) and exploratory/developmental grants (R21). Investigators can still submit trials through those parents. Individual institutes can also still issue targeted trial NOFOs "when there is a programmatic need," although NIH has not said how that need will be judged.
Parent participation is changing at the institute level, though. NHLBI has issued a notice (NOT-HL-27-001) withdrawing from the parent R01 clinical trial NOFO, PA-25-305, for due dates after November 5, 2026. NHLBI has its own track record here: it funded 218 investigator-initiated trials from FY2017 to FY2024 through a set of trial-type NOFOs. If you have been sending a cardiovascular, pulmonary or blood trial through the parent R01, read the NHLBI notice and the institute's current trial NOFOs before your next cycle.
How This Fits NIH's Broader Consolidation
The trial-type suite is the latest step in a reorganization that has been running all year:
- NOFO count. Active NOFOs fell from more than 800 at the start of 2025 to fewer than 500 by year's end, according to Drug Discovery and Development. We covered that cut in NIH's NOFO consolidation from 800 to 500.
- Career awards. NOT-OD-26-098 consolidates K awards and ends independent clinical trials on many of them. See our analysis of the K-award consolidation and clinical trial changes.
- Basic experimental studies with humans. NOT-OD-26-067 changed how these studies are classified, which affects whether a study counts as a clinical trial at all.
All three changes move NIH toward fewer, broader funding calls, with priorities set somewhere other than the NOFO itself.
There is precedent for the model. NCCIH moved most of its trials to a trial-type system in 2017, and NHLBI's FY2017 to FY2024 series shows a large institute can run one at scale.
Who Gains and Who Loses
Likely winners:
- Investigators doing work that crosses institutes. A trial of an exercise intervention for depression in heart failure patients has long had to choose between NHLBI and NIMH framing. A trial-type NOFO removes that choice, and NIH explicitly names easier co-funding as a goal.
- Methodologists and multi-site coordinating centers. Consistent instructions for each trial type reward groups that have mastered UG3/UH3 milestone planning.
- Experienced trialists in large programs. One set of instructions per trial type means less time adapting the same protocol to different institute formats.
Likely losers:
- Investigators in under-studied areas. Elizabeth Ginexi, a former NIH program officer quoted by Drug Discovery and Development, warned that disease-specific NOFOs send a funding signal for neglected conditions, and that signal disappears in a general call. Highlighted Topics and strategic plans signal priorities less strongly than a dedicated NOFO with set-aside funds.
- Early-career investigators. Without disease-specific NOFOs, new investigators have fewer obvious places to submit and must learn to read institute priorities from strategic plans and program officer conversations. That is the kind of knowledge established labs already have.
- Small trials that do not fit a category. A study that falls between feasibility and early efficacy, or a pragmatic study run at one site, may not clearly match any of the five types.
What to Do Before the NOFOs Post
- Classify your trial now. Using the table above, decide which of the five types your next trial fits. If it does not clearly fit one, change the design or plan to use the parent R01 or R21.
- Learn the activity codes. If you have only submitted R01s, the R61/R33 and UG3/UH3 phased structures need go/no-go milestones, transition criteria and often a separate review of the second phase. Start drafting milestones now.
- Find your institute's Highlighted Topics. In the new model, these and institute strategic plans carry the priority signal. Read them for your target institute and cite them in your Specific Aims.
- Talk to program officers before you write. With general calls, the program officer conversation is how you learn which institute will actually fund the work. Ask which institute would be the assigned institute, whether co-funding is realistic, and whether they expect the new trial-type NOFO or a parent to be the better route.
- Check every parent announcement you rely on. NHLBI's PA-25-305 withdrawal shows that institute participation in parents can change between cycles. Confirm your institute is still listed before each due date.
- Watch the NIH Guide. The suite will be posted in phases. Set a saved search for new clinical trial NOFOs with the R34, R61/R33 and UG3/UH3 activity codes. Our guide to NIH Guide NOFO discovery workflows covers how to set one up.
The Bottom Line
The five-NOFO suite would make NIH's trial funding easier to navigate for investigators who already know their way around and harder for those who relied on disease-specific calls to find a home. Nothing changes until the NOFOs are posted. Investigators who classify their trials, learn the phased activity codes and keep in close contact with their program officers will be best placed when they are.
If you are planning a clinical trial application for 2027, Granted can help you find the right NIH funding opportunity, match your design to its trial type and draft milestone-based aims for phased awards.